GLUE
Company Description
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 123.67M | 75.62M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (38.63M) | (72.70M) | (135.35M) | (108.50M) | (73.96M) | (35.88M) | (8.02M) |
| EPS | -0.59 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Free Cash Flow | (27.50M) | 38.01M | (62.84M) | (105.38M) | (69.09M) | (26.44M) | (7.56M) |
| FCF / Share | -0.42 | 0.51 | -1.22 | -2.23 | -1.48 | -0.60 | -0.17 |
| Operating CF | (22.80M) | 42.00M | (43.80M) | (92.47M) | (59.36M) | (23.05M) | (6.17M) |
| Total Assets | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M | 49.38M | 11.09M |
| Total Debt | 39.19M | 42.72M | 46.04M | 47.00M | 0 | 67.76M | 750,000 |
| Cash & Equiv | 129.88M | 224.25M | 128.10M | 54.91M | 346.07M | 41.70M | 6.00M |
| Book Value | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M | (48.73M) | (12.15M) |
| Return on Equity | -0.17 | -0.33 | -0.76 | -0.40 | -0.21 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.97M | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 4.70M | 1.06M | 0 | 0 |
| Net Income | (43.40M) | (44.50M) | (46.13M) | (27.08M) | (12.29M) | 46.88M | 13.44M | (23.86M) | (30.31M) | (31.97M) | (33.25M) | (34.88M) |
| EPS | -0.51 | -0.53 | -0.70 | -0.44 | -0.20 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 |
| Free Cash Flow | (48.84M) | (39.24M) | (43.78M) | 99.78M | (36.41M) | (47.08M) | 128.74M | (21.39M) | (29.79M) | (39.55M) | 27.95M | (26.36M) |
| FCF / Share | -0.57 | -0.47 | -0.67 | 1.61 | -0.59 | -0.57 | 2.10 | -0.26 | -0.42 | -0.66 | 0.49 | -0.53 |
| Operating CF | (44.11M) | (37.37M) | (43.01M) | 100.43M | (34.72M) | (45.49M) | 128.92M | (20.99M) | (27.77M) | (38.16M) | 29.63M | (24.71M) |
| Total Assets | 696.08M | 736.43M | 448.66M | 459.84M | 359.59M | 393.20M | 438.73M | 315.08M | 344.11M | 266.75M | 303.75M | 252.10M |
| Total Debt | 37.99M | 39.06M | 39.19M | 40.17M | 41.13M | 41.86M | 42.72M | 43.70M | 44.36M | 45.18M | 46.04M | 46.40M |
| Cash & Equiv | 90.10M | 159.86M | 129.88M | 208.34M | 69.43M | 78.53M | 224.25M | 125.58M | 108.85M | 99.75M | 128.10M | 59.05M |
| Book Value | 487.28M | 521.92M | 233.06M | 245.84M | 268.08M | 275.16M | 222.94M | 205.46M | 224.67M | 152.52M | 179.25M | 184.52M |
| Return on Equity | -0.09 | -0.09 | -0.20 | -0.11 | -0.05 | 0.17 | 0.06 | -0.12 | -0.13 | -0.21 | -0.19 | -0.19 |
